All In MedTech

Device Trial Radar · NCT03364114

Endorotor Resection In Refractory Barrett's Dysplasia Patients

Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

15

Actual

Start

Feb 9, 2018

Primary completion

Mar 24, 2026

Study completion Mar 24, 2026

Sponsor

Lead sponsor
Interscope, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 6, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 30 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the clinical trial is to evaluate the EndoRotor®'s ability to completely remove areas of Barrett's esophagus considered refractory after 3 failed ablation treatments (Radiofrequency Ablation (RFA) and/or Cryotherapy) or in patients with at least 1 failed ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duration of more than 24 hours.

Conditions

  • Barrett's Esophagus With Dysplasia

Interventions

  • EndoRotor Mucosal Resection SystemDevice

    The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.

  • Continued AblationDevice

    Continued ablation control shall include either cryotherapy or continued radial frequency ablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of complete removal of refractory Barrett's esophagusTime frame: 12 months
  2. Rate of device- and procedure-related serious adverse events (SAEs)Time frame: 12 months

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • The Mayo Clinic

    Rochester, Minnesota

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • NHS University College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.